Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.

NCT06907329 is registered in ClinicalTrials.gov with Qing Su as lead sponsor.

NCT NCT06907329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06907329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
Lead sponsor
Qing Su
Phase
Not applicable
Overall status
Recruiting
Start date
June 5, 2025
Completion date
March 31, 2027
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunosenescence, metabolism